Clinical importance of adherence to treatment with eicosapentaenoic acid by patients with hypercholesterolemia

Circulation Journal

Volumn 74, Issue 3, 2010, Pages 510-517

  Origasa, Hideki ^a   Yokoyama, Mitsuhiro ^b   Matsuzaki, Masunori ^c   Saito, Yasushi ^d   Matsuzawa, Yuji ^e  

^a UNIVERSITY OF TOYAMA   (Japan)

^b HYOGO PREFECTURAL AWAJI HOSPITAL   (Japan)

^c YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d CHIBA UNIVERSITY   (Japan)

^e SUMITOMO HOSPITAL   (Japan)

Author keywords

Adherence; Eicosapentaenoic acid; Hypercholesterolemia; Myocardial infarction

Indexed keywords

ICOSAPENTAENOIC ACID; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PREDICTIVE VALIDITY; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SECONDARY PREVENTION; SUDDEN DEATH; TREATMENT OUTCOME;

AGED; ALDEHYDE-LYASES; CORONARY ARTERY DISEASE; CYTOCHROME P-450 ENZYME SYSTEM; DEATH, SUDDEN, CARDIAC; DRUG THERAPY, COMBINATION; EICOSAPENTAENOIC ACID; FEMALE; FOLLOW-UP STUDIES; HEART DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INCIDENCE; KAPLAN-MEIERS ESTIMATE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MYOCARDIAL INFARCTION; PHARMACISTS; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 77649207189     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0746     Document Type: Article

References (37)

1. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-1307.
2. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, et al, for the MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): A prospective randomised controlled trial. Lancet 2006; 368: 1155-1163.
3. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al, for JELIS Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis. Lancet 2007; 369: 1090-1098.
4. Gehi AK, Ali S, Na B, Whooley MA. Self-reported medication adherence and cardiovascular events in patients with stable coronary heart disease: The heart and soul study. Arch Intern Med 2007; 167: 1798-1803.
5. Bennett SJ, Huster GA, Baker SL, Milgrom LB, Kirchgassner A, Birt J, et al. Characterization of the precipitants of hospitalization for heart failure decompensation. Am J Crit Care 1998; 7: 168-174.
6. Carlson B, Riegel B, Moser DK. Self-care abilities of patients with heart failure. Heart Lung 2001; 30: 351-359.
7. Ghali JK, Kadakia S, Cooper R, Ferlinz J. Precipitating factors leading to decompensation of heart failure: Traits among urban blacks. Arch Intern Med 1988; 148: 2013-2016.
8. Fletcher SW, Pappius EM, Harper SJ. Measurement of medication compliance in a clinical setting: Comparison of three methods in patients prescribed digoxin. Arch Intern Med 1979; 139: 635-638.
9. Coronary Drug Project Research Group. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med 1980; 303: 1038-1041.
10. Horwitz RI, Viscoli CM, Berkman L, Donaldson RM, Horwitz SM, Murray CJ, et al. Treatment adherence and risk of death after a myocardial infarction. Lancet 1990; 336: 542-545.
11. The West of Scotland Coronary Prevention Study Group. Compliance and adverse event withdrawal: Their impact on the West of Scotland Coronary Prevention Study. Eur Heart J 1997; 18: 1718-1724.
12. Ho PM, Spertus JA, Masoudi FA, Reid KJ, Peterson ED, Magid DJ, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 2006; 166: 1842-1847.
13. Rudnicka AR, Ashby D, Brennan P, Meade T. Thrombosis prevention trial: Compliance with warfarin treatment and investigation of a retained effect. Arch Intern Med 2003; 163: 1454-1460.
14. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. Lancet 2003; 362: 759-766.
15. Granger BB, Swedberg K, Ekman I, Granger CB, Olofsson B, McMurray JJ, for the CHARM Investigators. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: Double-blind, randomized, controlled clinical trial. Lancet 2005; 366: 2005-2011.
16. Brown SB, Shannon RP. Improving medication compliance in patients with heart failure. Am J Cardiol 2008; 101: 274-277.
17. Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006; 333: 15-18.
18. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, et al. Medication compliance and persistence: Terminology and definitions. Value Health 2008; 11: 44-47.
19. Jerant A, DiMatteo R, Arnsten J, Moore-Hill M, Franks P. Selfreport adherence measures in chronic illness: Retest reliability and predictive validity. Med Care 2008; 46: 1134-1139.
20. Yokoyama M, Origasa H. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: Rationale, design, and baseline characteristics. Am Heart J 2003; 146: 613-620.
21. Kohro T, Yamazaki T. Eicosapentaenoic acid (EPA) in reducing secondary cardiovascular events in hypercholesterolemic Japanese patients. Circ J 2009; 73: 1197-1198.
22. Lee SH, Shin MJ, Kim JS, Ko YG, Kang SM, Choi D, et al. Blood eicosapentaenoic acid and docosahexaenoic acid as predictors of all-cause mortality in patients with acute myocardial infarction: Data from infarction prognosis study (IPS) registry. Circ J 2009; 73: 2250-2257.
23. Ueda M, Doumei T, Takaya Y, Shinohata R, Katayama Y, Ohnishi N, et al. Serum N-3 polyunsaturated fatty acid levels correlate with the extent of coronary plaques and calcifications in patients with acute myocardial infarction. Circ J 2008; 72: 1836-1843.
24. Zeller A, Schroeder K, Peters TJ. An adherence self-report questionnaire facilitated the differentiation between nonadherence and nonresponse to antihypertensive treatment. J Clin Epidemiol 2008; 61: 282-288.
25. Walker EA, Molitch M, Kramer MK, Kahn S, Ma Y, Edelstein S, et al for the Diabetes Prevention Program Research Group. Adherence to preventive medications: Predictors and outcomes in the Diabetes Prevention Program. Diabetes Care 2006; 29: 1997-2002.
26. Qureshi NN, Hatcher J, Chaturvedi N, Jafar TH, for the Hypertension Research Group. Effect of general practitioner education on adherence to antihypertensive drugs: Cluster randomized controlled trial. BMJ 2007; 335: 1030-1033.
27. Daskalopoulou SS, Delaney JA, Filion KB, Brophy JM, Mayo NE, Suissa S. Discontinuation of statin therapy following an acute myocardial infarction: A population-based study. Eur Heart J 2008; 29: 2083-2091.
28. Saito Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Ishikawa Y, et al for the JELIS Investigators. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Sub-analysis of primary prevention cases from EPA Lipid Intervention Study (JELIS). Atherosclerosis 2008; 200: 135-140.
29. Matsuzaki M, Yokoyama M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, et al for the JELIS Investigators. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease: Secondary prevention analysis from JELIS. Circ J 2009; 73: 1283-1290.
30. Nielsen MW, Søndergaard B, Kjøller M, Hansen EH. Agreement between self-report data on medicine use and prescription records vary according to method of analysis and therapeutic group. J Clin Epidemiol 2008; 61: 919-924.
31. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006; 15: 565-574.
32. Sappok T, Faulstich A, Stuckert E, Kruck H, Marx P, Koennecke HC. Compliance with secondary prevention of ischemic stroke: A prospective evaluation. Stroke 2001; 32: 1884-1889.
33. Haynes RB, McDonald HP, Gang AX. Helping patients follow prescribed treatment: Clinical applications. JAMA 2002; 288: 2880-2883.
34. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: Scientific review. JAMA 2002; 288: 2868-2879.
35. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and lowdensity lipoprotein cholesterol: A randomized controlled trial. JAMA 2006; 296: 2563-2571.
36. Murray MD, Young J, Hoke S, Tu W, Weiner M, Morrow D, et al. Pharmacist intervention to improve medication adherence in heart failure: A randomized trial. Ann Intern Med 2007; 146: 714-725.
37. Gwadry-Sridhar F, Guyatt G, O'Brien B, Arnold JM, Walter S, Vingilis E, et al. TEACH: Trial of Education And Compliance in Heart dysfunction chronic disease and heart failure (HF) as an increasing problem. Contemp Clin Trials 2008; 29: 905-918.